Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Synthorx

Request full access

Biotechnology company using synthetic biology to synthesize solutions

San Diego, United StatesFounded 2014Biotech & Life Sciences

About Synthorx

Synthorx is a biotechnology company specializing in the design and development of protein therapeutics, known as Synthorins, aimed at treating cancer and autoimmune disorders. The company leverages a novel DNA base pair technology to create optimized and tailored medicines, representing a significant advancement in protein design. Synthorx primarily serves patients suffering from severe diseases, focusing on improving their quality of life through innovative medical solutions. Operating in the biopharmaceutical market, Synthorx's business model involves extensive research and development, followed by clinical trials to validate the efficacy of their therapeutics. Revenue is generated through the commercialization of these therapeutics, partnerships, and collaborations with other pharmaceutical companies. The company has successfully raised significant capital through public offerings and private funding rounds, enabling continuous innovation and expansion of their therapeutic pipeline.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

Synthorx in the San Diego ecosystem

Live from Dealroom

The Synthorx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$36M

29 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Synthorx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.